Neurophet AQUA

by Neurophet  · Based in South Korea → — AI-powered Brain Imaging Analysis for Neurodegenerative Diseases
Neurology Nuclear Medicine Radiology

One-off payment, subscription, pay-per-scan
Regulatory Status Disclosed

Overview

Neurophet AQUA is an artificial intelligence-based software solution designed for the quantitative analysis of brain MRI and PET images. It assists clinicians in the diagnosis, treatment planning, and monitoring of various neurodegenerative diseases, including Alzheimer’s disease, mild cognitive impairment, dementia, and multiple sclerosis. The software automates precise segmentation, volumetric quantification of brain structures and lesions, and detection of specific imaging biomarkers such as white matter hyperintensities, cerebral microbleeds, and edema. By providing objective evaluation, normative comparisons (for both Asian and Western populations), and intuitive analysis reports, Neurophet AQUA aims to streamline workflows, reduce manual tasks, and support informed, patient-specific clinical decision-making.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Fast and precise automatic quantification analysis of brain MRI
  • Precision brain MRI segmentation and volumetric analysis
  • Automated lesion localization and quantification (microbleeds, edema, WMH)
  • Quantitative analysis of MRI and PET images (including SUVR)
  • Comparison with normative reference data (Asian & Western populations)
  • Intuitive analysis reports and visualized graphs
  • Multi-time-point and longitudinal analysis for disease progression
  • Supports monitoring of treatment efficacy and side effects (e.g., ARIA)
  • Integration into standard reading environments (PACS)
  • Analysis of Multiple Sclerosis lesions and structural changes

Use Cases

  • Diagnosis and differential diagnosis of Alzheimer's disease and dementia
  • Monitoring of Alzheimer's disease treatment effects and adverse events (ARIA)
  • Evaluation of neurodegeneration and cognitive impairment
  • Analysis and monitoring of Multiple Sclerosis progression
  • Support for clinical trials and research imaging analysis
  • Predicting prognosis from mild cognitive impairment to dementia

What Physicians Need to Know

Brain MRI Analysis
Neurophet AQUA is an AI-based software designed for quantitative analysis of brain MRI data. It performs brain region segmentation, multi-time-point analysis, normative comparison, volume quantification, and white matter hyperintensity (WMH) quantification. It also offers advanced analysis for Multiple Sclerosis (MS) and WMH using T2-FLAIR images.
Neurodegenerative Disease Screening
The tool is specifically developed to assist in the diagnosis and monitoring of neurodegenerative diseases, including Mild Cognitive Impairment, Alzheimer's disease (AD), and dementia. It helps clinicians evaluate brain atrophy and white matter degeneration, and track disease progression. Neurophet AQUA AD Plus, an advanced version, integrates MRI and PET analysis for comprehensive Alzheimer's disease evaluation, including detection of cerebral microbleeds, superficial siderosis, and brain edema, and provides standardized uptake value ratio (SUVR) analysis for PET images.
Analysis Speed
Neurophet AQUA is capable of segmenting and analyzing brain images rapidly, typically within 5 minutes. This significantly reduces the time spent on analysis compared to conventional workflows, which can take several hours.
Physician Tip

Neurophet AQUA provides objective and quantitative analysis of brain MRI, which can be invaluable for diagnosing and monitoring neurodegenerative diseases like Alzheimer's and dementia. The rapid processing time allows for efficient integration into clinical workflows, aiding in early detection, tracking disease progression, and assessing treatment efficacy and potential side effects, especially with anti-amyloid antibody therapies. The intuitive reports with normative comparisons and longitudinal analysis capabilities can also facilitate clearer communication with patients and support personalized treatment strategies.

Neurophet AQUA is designed for integration into standard reading environments such as Picture Archiving and Communication Systems (PACS). It can be deployed locally on dedicated hardware. The solution also integrates with AI platforms like CARPL.AI. The Neurophet AQUA AD Plus version offers integrated analysis of both MRI and PET images, streamlining the evaluation process for Alzheimer's disease.

Details

Category Neurology AI, Radiology & Imaging AI
Pricing One-off payment, subscription, pay-per-scan — One-off payment; Subscription; Pay-per-scan
DeploymentLocally on dedicated hardware
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

Neurophet AQUA received its initial FDA 510(k) clearance in May 2023 for brain atrophy analysis. An updated version, Neurophet AQUA, received 510(k) clearance in November 2024 for Multiple Sclerosis analysis. Neurophet AQUA AD Plus, an expanded solution, received 510(k) clearance in February 2026 for comprehensive neuroimaging analysis related to Alzheimer's disease, including the detection of microbleeds and edema.

Integrations
EHR Not specified
Specialties Neurology, Nuclear Medicine, Radiology

What the Web Says

Neurophet AQUA is a medical device that automatically segments and quantifies brain atrophy from MRI scans, providing objective data for diagnosing and managing neurodegenerative diseases like Alzheimer's. Reviews highlight its potential to improve diagnostic accuracy and efficiency for physicians, though some sources are limited or not directly from physician reviews.

Overall: Positive

Strengths

  • Automated brain atrophy quantification saves time for clinicians.
  • Provides objective data to support diagnosis and monitoring of neurodegenerative diseases.
  • Aids in early detection and intervention for conditions like Alzheimer's.
  • Potentially reduces inter-reader variability in MRI analysis.
  • User-friendly interface (implied from product descriptions).
  • FDA cleared, indicating regulatory approval and safety.

Limitations

  • Limited direct physician reviews publicly available on common platforms like G2/Capterra/Reddit.
  • Integration challenges with existing healthcare IT systems are not explicitly discussed but are common for new tech.
  • Cost of implementation and ongoing use is not readily available in public reviews.
  • Reliance on high-quality MRI scans for accurate results.
  • Potential learning curve for new users, though likely minimal.
  • Specific performance metrics (e.g., sensitivity, specificity) in real-world clinical settings are not widely detailed in general reviews.

Based on reviews from: Neurophet Official Website, Medical Technology News Articles, Healthcare IT Industry Publications, Academic Research Papers (abstracts/mentions), FDA Clearance Announcements

Last updated: 2026-07-19

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Neurophet AQUA

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money
No press coverage or publications on file yet. Know of some? Suggest an edit →

Videos

Product demos, reviews, and walkthroughs for Neurophet AQUA.

View all on YouTube

Frequently Asked Questions

Neurophet AQUA is an AI-based software designed for the quantitative analysis of brain MRI data, aiding in the diagnosis and management of neurodegenerative diseases such as Alzheimer's disease, mild cognitive impairment, and dementia. It automates the labeling, visualization, and volumetric quantification of brain structures and lesions, providing objective data for clinical evaluation and monitoring.
Neurophet AQUA, along with its upgraded version AQUA AD Plus and Neurophet SCALE PET, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), validating its safety and effectiveness. It also holds CE Certification (Class IIa) and MHLW (Japan) certification, demonstrating compliance with international medical device standards.
Neurophet AQUA offers comparable segmentation accuracy and reliability to established tools like FreeSurfer, but with significantly faster processing times, typically completing analysis within 1-10 minutes. This efficiency makes it well-suited for clinical applications requiring rapid and accurate brain MRI processing.
Neurophet AQUA is available through various pricing models, including one-off payments, subscriptions, or a pay-per-scan basis. In some regions, such as Japan, the product has received health insurance coverage and qualifies for additional reimbursement for medical institutions utilizing qualified AI software.
While Neurophet AQUA provides valuable quantitative analysis and comparison to normative data, it is intended as a supportive tool and not a standalone basis for diagnostic decision-making. Clinical interpretation must always be performed by qualified healthcare professionals.
Yes, Neurophet AQUA is designed for seamless integration into standard reading environments, such as Picture Archiving and Communication Systems (PACS). This allows for efficient incorporation into existing hospital workflows, streamlining the process from image acquisition to analysis and reporting.
Yes, Neurophet AQUA supports multi-time-point and longitudinal analysis, enabling clinicians to track changes in brain atrophy and white matter hyperintensities over time. This feature is crucial for assessing disease progression, monitoring treatment efficacy, and helping to predict prognosis in patients with cognitive impairment.

Related Tools

Cercare Medical Oncology Virtual Expert
Cercare Medical
Neurology AI
Cercare Medical's Oncology Virtual Expert is an AI-powered brain tumor segmentation module that provides fast, consistent, and semi-automated tumor analysis from standard MRI data, designed for on-premise deployment within existing clinical radiology workflows.
CoLumbo C-Spine
Smart Soft Healthcare AD
Clinical Decision Support & Reference
CoLumbo C-Spine is an AI-powered software that processes and analyzes cervical spine MRI exams, assisting clinicians in diagnosis and assessment.
MeRT System
Wave Neuroscience
Mental & Behavioral Health AI
MeRT (Magnetic e-Resonance Therapy) is an advanced, personalized form of TMS that uses your own brainwave data to guide treatment. It's a non-invasive, drug-free option designed to help the brain communicate more efficiently so symptoms of conditions like depression, anxiety, PTSD, TBI, autism, and more can improve.
Brainomix 360 Hyperdensity
Brainomix Limited
Neurology AI
Brainomix 360 Hyperdensity is an AI-powered neuroimaging software tool that detects and quantifies brain hyperdensities on CT scans, forming a crucial part of the Brainomix 360 Stroke platform for rapid and accurate stroke assessment.
SOMNUM
HoneyNaps
Clinical Decision Support & Reference
SOMNUM is an AI-enabled medical software tool by Honeynaps Co., Ltd. that provides comprehensive sleep analysis to aid in the diagnosis and management of sleep disorders.
DETECT-ME/CFS project
DETECT-ME/CFS project (ME/CFS Research Foundation)
Clinical Decision Support & Reference
The DETECT-ME/CFS project is developing an AI-supported clinical decision support system to improve the rapid and reliable diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

See all Neurology AI tools →

Suggest an Edit → | Last Verified: 2026-04-18 | First Added: 2026-04-18
AI Tool Finder
AI-powered search. Results may not be comprehensive.